All articles by GlobalData Healthcare

Using artificial intelligence to enhance regenerative medicine

As the field of regenerative medicine continues to advance, the incorporation of AI is playing a transformative role in the…
Ryoncil, the first FDA-approved mesenchymal stromal cell therapy

Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, regeneration, or replacement…
Exelixis focuses on future growth despite COSMIC-313 trial challenges

At the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the…
SCOPE 2025: investors share optimism and obstacles for AI in clinical operations

Clinical operations teams can expect a tremendous return on investments in artificial intelligence (AI) in the next 5–10 years, according…
Pfizer’s bet on gene therapies in haemophilia has been a bust

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft demand for…

NICE approval of Casgevy: a new era for sickle cell disease treatments in the UK

In late 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) for sickle cell…
FDA approvals decline but drug innovation remains strong even among small sponsors

The US Food and Drug Administration (FDA) approved 126 innovator and biosimilar drugs in 2024, significantly lower than the 149…
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling strong investor confidence…
GLP-1 receptor agonists could hold promise for opioid use disorder treatment

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby…
DMD market expected to grow to $5.2bn in the 7MM by 2033

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, the…